Goldman Sachs Group Inc Immunic, Inc. Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $15,747 - $21,135	13,814 New	13,814 $18,000
Q1 2023 May 14, 2024	BUY	$1.35 - $2.87 $26,065 - $55,413	19,308 Added 135.37%	33,571 $50,000
Q1 2023 May 11, 2023	BUY	$1.35 - $2.87 $45,320 - $96,348	33,571 New	33,571 $50,000
Q3 2022 May 14, 2024	SELL	$3.0 - $5.49 $37,884 - $69,327	-12,628 Reduced 46.96%	14,263 $45,000
Q3 2022 Nov 10, 2022	SELL	$3.0 - $5.49 $37,884 - $69,327	-12,628 Reduced 46.96%	14,263 $0
Q2 2022 May 14, 2024	BUY	$3.13 - $12.25 $84,168 - $329,414	26,891 New	26,891 $93,000
Q2 2022 Aug 15, 2022	SELL	$3.13 - $12.25 $686,189 - $2.69 Million	-219,230 Reduced 89.07%	26,891 $93,000
Q1 2022 May 16, 2022	BUY	$9.54 - $14.26 $667,828 - $998,242	70,003 Added 39.75%	246,121 $2.78 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $60,488 - $84,470	8,241 Added 4.91%	176,118 $1.69 Million
Q3 2021 Nov 10, 2021	BUY	$8.05 - $13.29 $1.35 Million - $2.23 Million	167,877 New	167,877 $1.49 Million

55.8M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $28.7M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.